Efficacy and safety of umifenovir for coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis.
J Med Virol
; 93(1): 481-490, 2021 01.
Article
in English
| MEDLINE | ID: covidwho-1206788
ABSTRACT
We conducted this systemic review and meta-analysis in an attempt to evaluate the efficacy and safety of umifenovir in coronavirus disease 2019 (COVID-19). We searched PubMed, Web of Science, Embase, Cochrane Library, China National Knowledge Infrastructure, and medRxiv database. We included both retrospective and prospective studies. The mean difference (MD) and risk ratio (RR) with 95% confidence intervals (CI) were applied to assess the effectiveness of umifenovir for COVID-19. A total of 12 studies with 1052 patients were included in our final studies. Compared with control group, umifenovir was associated with higher negative rate of PCR on day 14 (RR1.27; 95% CI 1.04 to 1.55). However, umifenovir is not related to nucleus acid negative conversion time (MD 0.09; 95% CI -1.48 to 1.65), negative rate on day 7 (RR1.09; 95% CI 0.91 to 1.31), incidence of composite endpoint (RR1.20; 95% CI 0.61 to 2.37), rate of fever alleviation on day 7 (RR1.00; 95% CI 0.91 to 1.10), rate of cough alleviation on day 7 (RR1.00; 95% CI 0.85 to 1.18), or hospital length of stay (MD 1.34; 95% CI -2.08 to 4.76). Additionally, umifenovir was safe in COVID-19 patients (RR for incidence of adverse events 1.29; 95% CI 0.57 to 2.92). The results of sensitivity analysis and subgroup analysis were similar to pooled results. There is no evidence to support the use of umifenovir for improving patient-important outcomes in patients with COVID-19.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Antiviral Agents
/
SARS-CoV-2
/
COVID-19 Drug Treatment
/
Indoles
Type of study:
Cohort study
/
Experimental Studies
/
Observational study
/
Prognostic study
/
Reviews
/
Systematic review/Meta Analysis
Limits:
Humans
Language:
English
Journal:
J Med Virol
Year:
2021
Document Type:
Article
Affiliation country:
Jmv.26256
Similar
MEDLINE
...
LILACS
LIS